Becton Dickinson & Co
BDX
180.16
-0.14
-0.08%
Becton Dickinson & Co
US · BDX
#450 by market cap
Listed 1970
180.16
-0.14
-0.08%
Live - 5344 symbols - heartbeat 73s ago
· 2026-10-07 22:47
After-hours
180.16
0.00%
Overnight
179.27
-0.49%
- Market cap
- 49.07B
- P/E (TTM)i
- 54.43
- P/Bi
- 2.01
- EPSi
- 5.82
- Div yieldi
- 2.33%
- 52W posi
- 83%
Reader sentiment
Are you bullish or bearish on BDX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 9 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 98.44% -0.07pp
- Institutions
- 1,685 -9
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund86.27%
Public Company3.81%
Private Company2.11%
Government Pension Fund1.87%
Sovereign Wealth Fund1.58%
Hedge Fund1.28%
Insurance Company0.79%
Family Office/Trust0.28%
Individual/Insider0.17%
Other1.85%
Top holders as of 2026-06-30
BlackRock
9.03% · 24.59M sh
Vanguard Capital Management, LLC
7.17% · 19.54M sh
State Street Global Advisors
5.51% · 15.00M sh
Vanguard Portfolio Management, LLC
5.50% · 14.97M sh
First Eagle Investment Management, LLC
5.07% · 13.82M sh
Geode Capital Management, LLC
2.99% · 8.14M sh
T. Rowe Price Group, Inc.
2.80% · 7.63M sh
MFS Investment Management
2.75% · 7.50M sh
Invesco Ltd.
2.66% · 7.25M sh
Putnam LLC
2.46% · 6.69M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 24 buys · 21 sells
| Name | Role | Stake |
|---|---|---|
| Thomas Polen | Chairperson & CEO | 0.04% |
| Timothy Ring | Independent Director | 0.02% |
| Bilal Muhsin | Executive VP & President of Future Connected Care Segment | 0.02% |
| Bertram Scott | Lead Independent Director | 0.01% |
| Christopher Ian Jones | Independent Director | 0.01% |
| Shana Neal | Executive Vice President | 0.01% |
| Michael Feld | Executive VP & President of the Life Sciences Segment | 0.01% |
| Christopher DelOrefice | Chief Financial Officer | 0.01% |
| Roland Goette | Executive VP & President of EMEA | 0.01% |
| Michael Garrison | Executive VP & President of Medical segment | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-27 | Michael Feld | Executive VP & President of the Life Sciences Segment | Automatic Disposition | -76 | $183.70 |
| 2026-09-01 | vitor Roque | SVP of Finance, Business Units and Corporate Financial Planning & Analysis | Sale to Issuer | -190 | -- |
| 2026-08-25 | Michael Feld | Executive VP & President of the Life Sciences Segment | Automatic Disposition | -165 | $188.49 |
| 2026-08-19 | Michael Feld | Executive VP & President of the Life Sciences Segment | Sale to Issuer | -1,049 | -- |
| 2026-08-12 | Thomas Polen | Chairperson & CEO | Derivative Exercise and Sale | -43,278 | $167.25–185.00 |
| 2026-08-10 | Roland Goette | Executive VP & President of EMEA | Open Market Disposition | -2,438 | $180.84 |
| 2026-08-05 | Robert Huffines | Independent Director | Other Derivative Acquisition | +189 | -- |
| 2026-08-05 | Carrie Byington | Independent Director | Other Derivative Acquisition | +94 | -- |
| 2026-07-26 | Michael Feld | Executive VP & President of the Life Sciences Segment | Automatic Disposition | -75 | $157.13 |
| 2026-07-01 | Bilal Muhsin | Executive VP & President of Future Connected Care Segment | Sale to Issuer | -1,935 | -- |
| 2026-06-30 | Bilal Muhsin | Executive VP & President of Future Connected Care Segment | Other Acquisition | +14,342 | -- |
| 2026-06-25 | Michael Feld | Executive VP & President of the Life Sciences Segment | Automatic Disposition | -75 | $152.80 |
| 2026-06-23 | Michael Garrison | Executive VP & President of Medical segment | Automatic Disposition | -1,100 | $145.66 |
| 2026-06-21 | Manish Sinha | Executive Vice President | Initial Statement of Beneficial | 0 | -- |
| 2026-06-09 | Michael Garrison | Executive VP & President of Medical segment | Automatic Disposition | -1,100 | $151.48 |
| 2026-05-31 | Thomas Polen | Chairperson & CEO | Derivative Exercise and Sale | -20,209 | $126.16–146.35 |
| 2026-05-31 | Peter Menziuso | Executive VP & President of Bd Interventional | Other Acquisition | +14,258 | -- |
| 2026-05-31 | Peter Menziuso | Executive VP & President of Bd Interventional | Initial Statement of Beneficial | 0 | -- |
| 2026-05-25 | Michael Feld | Executive VP & President of the Life Sciences Segment | Automatic Disposition | -75 | $147.35 |
| 2026-05-07 | Robert Huffines | Independent Director | Other Derivative Acquisition | +210 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 22:47:28 · For reference only, not investment advice and not tailored to your situation.